FORM 4

obligations may continue. See Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Silva Paul M				RTEX PHAR [VRTX]		_	,		c all applicable) Director Officer (give title	10% (Owner (specify		
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED				ate of Earliest Transa	action (N	/lonth/	Day/Year)		SVP & Corp Controlle		,		
50 NORTHERN AVENUE				Amendment, Date of	f Origina	ıl Filed	i (Month/Day/		6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street)									X	Form filed by On	e Reporting Pers	son	
BOSTON	MA	02210								Form filed by Mo Person	re than One Rep	oorting	
(City)	(State)	(Zip)											
		Table I - No	n-Derivative	Securities Acq	uired	, Dis	posed of,	or Bei	neficially	Owned			
			2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Disposed Of			5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
					Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)	
Common Stock			02/01/2018		M		8,594	A	\$96.87	25,228	D		
Common Stock			02/01/2018		S ⁽¹⁾		8,594	D	\$174.11	16,634	D		
Common Stock			02/02/2018		М		1,289	A	\$91.05	17,923	D		
Common Stock			02/02/2018		S ⁽¹⁾		1,289	D	\$169.42	16,634	D		
Common Stock										169	I	401(k)	
		Table II -	Derivative S	ecurities Acqu	ired.	Disp	osed of, c	or Bene	eficially C	wned			

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$96.87	02/01/2018		М			8,594	(2)	07/14/2024	Common Stock	8,594	\$0.00	1,719	D	
Stock Option (Right to Buy)	\$91.05	02/02/2018		M			1,289	(3)	02/01/2026	Common Stock	1,289	\$0.00	10,313	D	

Explanation of Responses:

- 1. Transaction made pursuant to Mr. Silva's company-approved trading plan under Rule 10b5-1.
- 2. The option vests in 16 quarterly installments from 7/15/2014.
- 3. The option vests in 16 quarterly installments from 2/2/2016.

Remarks:

/s/ Omar White, Attorney-in-

02/05/2018

Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.